

Highlights in Multiple Myeloma from the Annual ASCO and EHA 2022 Meetings

References

1. Richardson PG, Jacobus SJ, Weller EA, et al. Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. *N Engl J Med*. 2022;387:132-147.
2. Askeland FB, Haukås F, Slørdahl TS, et al. Replacing steroids in transplant-ineligible multiple myeloma: The phase 2 isatuximab-bortezomib-lenalidomide-dexamethasone REST study. Abstract P888. EHA Annual Congress 2022.
3. Groen K, Seefat M, Nasserinejad K, et al. Ixazomib, daratumumab and low dose dexamethasone in frail patients with newly diagnosed multiple myeloma (NDMM): Results of the maintenance treatment of the phase II HOVON 143 study. Abstract P906. EHA Annual Congress 2022.
4. Dytfeld D, Wróbel T, Jamroxiak K, et al. ATLAS: A phase 3 randomized trial of carfilzomib, lenalidomide, and dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma. Abstract S175. EHA Annual Congress 2022.
5. Popat R, Usmani S, Garfall A, et al. P06: Updated results from the phase 1/2 MajesTEC-1 study of teclistamab, a B-cell maturation antigen X CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma. *HemaSphere*. 2022;6:14.
6. Zonder JA, Richter J, Bumma N, et al. Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome with REGN5458, a BCMAxCD3 Bispecific Monoclonal Antibody, in a Phase 1/2 First-in-Human Study in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Abstract S189. EHA 2022 Annual Congress.
7. Minnema MC, Krishnan AY, Berdeja JG, et al. Efficacy and safety of talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated results from MonumentAL-1. *J Clin Oncol*. 2022;40(suppl 16):8015.
8. Lesokhin AM, Arnulf B, Niesvizky R, et al. Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM). Abstract 8006. ASCO Annual Meeting 2022.
9. Minnema MC, Krishnan AY, Berdeja JG, et al. Efficacy and safety of talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated results from MonumentAL-1. Abstract 8015. ASCO Annual Meeting 2022.
10. Van de Donk NWJC, Bahlis N, Mateos M-V, et al. Novel combination immunotherapy for treatment of relapsed/refractory multiple myeloma: updated phase 1B results for talquetamab (A GPRC5D X CD3 bispecific antibody) in combination with daratumumab. Abstract S183. EHA 2022 Annual Congress.
11. Otero PR, D'Souza A, Reece D, et al. Teclistamab in combination with daratumumab, a novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma: Updated phase 1B results. Abstract S188. EHA 2022 Annual Congress.
12. Du J, Jiang H, Dong B, et al. Updated results of a multicenter first-in-human study of BCMA/CD19 Dual-targeting Fast CAR-T GC012F For Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Abstract S186. EHA 2022 Annual Congress.

Provided by MediCom Worldwide, Inc.
This activity is not commercially supported.